CLAIMS:

1. A pharmaceutically acceptable salt of the compound of Formula (I),



Formula (I),

or a solvate thereof,

wherein the pharmaceutically acceptable salt is selected from the group consisting of an ethanolamine salt, a *tert*-butylamine salt, a potassium salt, a meglumine salt, a tris(hydroxymethyl)aminomethane salt, a lysine salt, and an ammonium salt.

2. The pharmaceutically acceptable salt or a solvate thereof according to claim 1, wherein the pharmaceutically acceptable salt is an ethanolamine salt or a *tert*-butylamine salt;

optionally wherein the pharmaceutically acceptable salt is an ethanolamine salt.

3. The pharmaceutically acceptable salt or a solvate thereof according to any one of the preceding claims, wherein the pharmaceutically acceptable salt or a solvate thereof is a solid form;

optionally wherein the pharmaceutically acceptable salt or a solvate thereof is a crystalline form.

4. The pharmaceutically acceptable salt or a solvate thereof according to any one of the preceding claims, having a bioavailability of at least 39 F%, or from 39 F% to 82 F%, or from 50 F% to 82 F%, or from 64 F% to 82 F%.

5. The pharmaceutically acceptable salt or a solvate thereof according to any one of the preceding claims, having a water sorption of less than 1.7% at 25 °C and 80% relative humidity as determined by dynamic vapor sorption.

6. The pharmaceutically acceptable salt or a solvate thereof according to any one of the preceding claims, having a weight loss of from 0.07% to 8.94% as determined by thermogravimetric analysis when heated from 25 °C to 120 °C;

optionally wherein the crystalline form has a weight loss of from 0.07% to 0.94% as determined by thermogravimetric analysis when heated from 25 °C to 120 °C.

7. The pharmaceutically acceptable salt or a solvate thereof according to any one of the preceding claims, having one or more of the following properties:

- a solubility of from 2.5 mg/ml to greater than 5.0 mg/ml at 24 hours in FaSSIF media (pH 7.5);
- a solubility of from 3.4 mg/ml to greater than 5.0 mg/ml at 24 hours in FeSSIF media (pH 7.8);
- a solubility of from 0.07 mg/ml to 0.090 mg/ml at 24 hours in media at pH 6.8.

8. The pharmaceutically acceptable salt or a solvate thereof according to any one of the preceding claims, wherein the pharmaceutically acceptable salt or a solvate thereof is a crystalline form of the ethanolamine salt of the compound of Formula (I).

9. The pharmaceutically acceptable salt or a solvate thereof according to claim 8, having one or more of the following properties:

- a bioavailability of 82 F%;
- a water sorption of 0.49% at 25 °C and 80% relative humidity as determined by dynamic vapor sorption;
- an endothermic onset of 176 ºC as measured by differential scanning calorimetry;
- a melting point of 178 ºC as measured by differential scanning calorimetry;

- a weight loss of 0.10% as determined by thermogravimetric analysis when heated from 25 °C to 120 °C;
- a solubility of greater than 7.99 mg/ml at 24 hours in FaSSIF media (pH 7.5);
- a solubility of greater than 8.02 mg/ml at 24 hours in FeSSIF media (pH 7.8);
- a solubility of 0.088 mg/ml at 24 hours in media at pH 6.8.

10. The pharmaceutically acceptable salt or a solvate thereof according to claim 8, wherein the crystalline form exhibits an X-ray powder diffraction pattern having at least one peak selected from 6.6 ±0.2, 11.7 ±0.2, 15.0 ±0.2, 15.9 ±0.2, 17.7 ±0.2, 18.7 ±0.2, 19.2 ±0.2, 23.7 ±0.2, and 26.6 ±0.2 degrees 2θ;

optionally wherein the crystalline form exhibits an X-ray powder diffraction pattern having at least two, at least three, at least four, or at least five peaks selected from 6.6 ±0.2, 11.7 ±0.2, 15.0 ±0.2, 15.9 ±0.2, 17.7 ±0.2, 18.7 ±0.2, 19.2 ±0.2, 23.7 ±0.2, and 26.6 ±0.2 degrees 2θ.

11. The pharmaceutically acceptable salt or a solvate thereof according to claim 8, wherein the crystalline form is an ethanolamine salt of the compound of Formula (I) and the crystalline form exhibits a single X-ray crystallographic analysis with the following parameters:

Parameter	**Value**
Molecular formula	$C_{20}H_{16}NO_5 \cdot C_2H_8NO$
Formula weight	412.43
space group	$P2_1/c$ (No. 14)
a, Å	4.7710 ± (8)
b, Å	29.645 ± (4)
c, Å	14.223 ± (2)
α, deg	90
β, deg	90.120 ± (11)
γ, deg	90
V, Å^3	2011.6 (5)
Z	4
temperature, K	170
radiation (wavelength, Å)	Cu Kα (1.54178)

.

12. A pharmaceutical composition comprising the pharmaceutically acceptable salt or a solvate thereof according to any one of claims 1 to 11, and a pharmaceutically acceptable excipient.

13. The pharmaceutical composition according to claim 12, wherein at least about 80%, at least 85%, at least 88%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, or at least 95% of pharmaceutically acceptable salt or a solvate thereof is the crystalline Form I of the ethanolamine salt.

14. Use of a pharmaceutically acceptable salt or a solvate thereof according to any one of claims 1 to 11, or a pharmaceutical composition according to claim 12 or claim 13, in the manufacture of a medicament for the treatment, prevention or amelioration of a fibrotic, inflammatory or proliferative disease or condition in a subject.

15. The use according to claim 14, wherein any one or more of the following apply:

a) the fibrotic, inflammatory or proliferative disease or condition is selected from fibrosis of skin, lung, heart, kidney, pancreas, eye and liver;

b) the fibrotic, inflammatory or proliferative disease or condition is selected from diabetic cardiomyopathy, congestive heart failure, ischemic heart disease, hypertension, peripheral artery disease, cerebrovascular disease, kidney disease, systemic sclerosis (scleroderma), hypertrophic scars, keloids, pulmonary fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), primary biliary cirrhosis (PBC), and primary sclerosis cholangitis (PSC);

c) the fibrotic, inflammatory or proliferative disease or condition is a kidney disease;

d) the fibrotic, inflammatory or proliferative disease or condition is selected from chronic kidney disease, progressive kidney disease, diabetic nephropathy, diabetic kidney disease, glomerulonephritis, focal segmental glomerulosclerosis, systemic lupus, lupus nephritis, primary glomerulonephritis,

membranous nephropathy, membranoproliferative glomerulonephritis, diffuse proliferative glomerulonephritis, membranous focal segmental glomerulosclerosis, secondary glomerulonephritis, membranous nephropathy, IgA nephropathy, or ischemic nephropathy;

e) the fibrotic, inflammatory or proliferative disease or condition is selected from chronic obstructive pulmonary disorder (COPD), asthma, and cystic fibrosis;

f) the fibrotic, inflammatory or proliferative disease or condition is a cancer; optionally wherein the cancer is selected from a breast cancer, skin cancer (melanoma), pancreatic cancer, lung cancer, prostate cancer, colon cancer, liver cancer (hepatocellular carcinoma), head and neck cancer, ovarian cancer and kidney cancer;

g) the fibrotic, inflammatory or proliferative disease or condition is an autoimmune disease or condition; optionally wherein the autoimmune disease or condition is selected from systemic lupus erythematosus (SLE), inflammatory bowel disease, Crohn’s disease, ulcerative colitis, graft versus host disease, multiple sclerosis, and rheumatoid arthritis;

h) the subject is a human.